EXEL

Exelixis Inc

EXEL, USA

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

https://www.exelixis.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EXEL
stock
EXEL

RBC Capital Maintains Exelixis(EXEL.US) With Hold Rating, Maintains Target Price $45 富途牛牛

Read more →
EXEL
stock
EXEL

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Exelixis (EXEL) and Natera (NTRA) The Globe and Mail

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$45

Analyst Picks

Strong Buy

7

Buy

4

Hold

9

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

18.56

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

5.27

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

8.96 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

High

6.86 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

48.32 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.31

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 88.24% of the total shares of Exelixis Inc

1.

BlackRock Inc

(11.1659%)

since

2025/06/30

2.

Vanguard Group Inc

(10.2039%)

since

2025/06/30

3.

Farallon Capital Management, L.L.C.

(5.9567%)

since

2025/06/30

4.

Renaissance Technologies Corp

(5.8765%)

since

2025/06/30

5.

State Street Corp

(4.229%)

since

2025/06/30

6.

iShares Core S&P Mid-Cap ETF

(3.2974%)

since

2025/08/31

7.

Fuller & Thaler Asset Management Inc

(3.2598%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(3.0276%)

since

2025/07/31

9.

FullerThaler Behavioral Sm-Cp Eq R6

(2.913%)

since

2025/06/30

10.

FullerThaler Behavioral Small-Cap Equity

(2.913%)

since

2025/06/30

11.

LSV Asset Management

(2.905%)

since

2025/06/30

12.

AQR Capital Management LLC

(2.8254%)

since

2025/06/30

13.

Geode Capital Management, LLC

(2.7658%)

since

2025/06/30

14.

Vanguard Small Cap Index

(2.3361%)

since

2025/07/31

15.

Amvescap Plc.

(2.0675%)

since

2025/06/30

16.

Arrowstreet Capital Limited Partnership

(1.9549%)

since

2025/06/30

17.

Dimensional Fund Advisors, Inc.

(1.3972%)

since

2025/06/30

18.

Morgan Stanley - Brokerage Accounts

(1.3294%)

since

2025/06/30

19.

Vanguard Small Cap Growth Index Inv

(1.3153%)

since

2025/07/31

20.

Charles Schwab Investment Management Inc

(1.2021%)

since

2025/06/30

21.

Qube Research & Technologies

(1.1319%)

since

2025/06/30

22.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0892%)

since

2025/07/31

23.

SPDR® S&P Biotech ETF

(1.0518%)

since

2025/08/31

24.

NORGES BANK

(1.0291%)

since

2025/06/30

25.

Nuveen, LLC

(1.0058%)

since

2025/06/30

26.

FMR Inc

(1.0031%)

since

2025/06/30

27.

Stephens Inv Mgmt Group LLC

(0.9816%)

since

2025/06/30

28.

Bank of America Corp

(0.9802%)

since

2025/06/30

29.

Invesco S&P MidCap Quality ETF

(0.8649%)

since

2025/08/29

30.

SPDR® S&P MIDCAP 400 ETF Trust

(0.776%)

since

2025/07/31

31.

Vanguard Explorer Inv

(0.7067%)

since

2025/06/30

32.

iShares Biotechnology ETF

(0.5848%)

since

2025/08/31

33.

Stephens SMID Select Growth

(0.5825%)

since

2025/06/30

34.

iShares S&P Mid-Cap 400 Growth ETF

(0.5771%)

since

2025/08/31

35.

Fidelity Extended Market Index

(0.5464%)

since

2025/07/31

36.

iShares Russell Mid-Cap Growth ETF

(0.5329%)

since

2025/08/31

37.

Schwab US Small-Cap ETFâ„¢

(0.4811%)

since

2025/08/30

39.

Invesco S&P MidCap Momentum ETF

(0.452%)

since

2025/08/29

40.

State St S&P Midcap® Indx SL Cl II

(0.4492%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.78

EPS Estimate

0.6931

EPS Difference

0.0869

Surprise Percent

12.5379%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(8)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(9)
GARP
Fair GARP(5.5)
Growth
Moderate Growth(4)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(4)
Quality
High Quality(8.5)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.